Werewolf Therapeutics provides business update, highlights 2025 outlook

Werewolf Therapeutics (HOWL) provided a business update and outlined its strategic outlook and expected milestones for 2025. “2024 was a year of execution for Werewolf in which we reported data from both of our clinical programs, highlighting promising durable anti-tumor activity with unprecedented tolerability for cytokine therapeutics. These data reinforced our INDUKINETM design, establishing that we could reproducibly improve the therapeutic index in an outpatient setting with a potentially best-in-class profile for WTX-124,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. “We continue to advance WTX-124 as a monotherapy and in combination with pembrolizumab in expansion arms and anticipate sharing preliminary monotherapy data in one or more expansion arms in the first half of 2025. We expect these data to guide the next steps of the development program, and pending additional insight from the data, we intend to engage with regulators to discuss potential registrational pathways. We further anticipate sharing data from combination expansion arms in the fourth quarter of 2025.”